Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (245)	1/9/2007 1:23:16 PM
From: Mike McFarland	Respond to of 360

Sorry--I don't have a date or anything for this short review essay. Although I suspect it is a PR type of paper that Gene Logic had to pay for to place, it does point to several studies and is a pretty readable discussion for the non-biotechie regarding pharmacogenomics. Biomarkers From Bench to Bedside: Are We There Yet? Kulkarni Prakash, PhD, Scientific Director, Cardiovascular and Metabolic Disorders; Dean Keser, MBA, Vice President, Genomics; Eric Kaldjian, MD, Senior Scientific Director, Pharmacogenomics and Oncology; and Jarlath ffrench-Mullen, PhD, Scientific Director, Central Nervous System Disorders, Gene Logic Inc., Gaithersburg, Md. google.com ------ Obviously, Wall Street does not consider Gene Logic to have anything of value in this area besides some cash and a ticker--but Wall Street could be wrong. GLGC was up nearly 20 cents a share in the past couple days, but naturally time to give that back, ha! Pathetic! Interesting article in the WSJ today about dark pool trading. Made me think about that 10% position. Would love to see that position traded over to a biotech fund, rather than stuck (oddly) in some family trust...